BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2147 related articles for article (PubMed ID: 17284714)

  • 1. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracyclines, mitoxantrone, radiotherapy, and granulocyte colony-stimulating factor: risk factors for leukemia and myelodysplastic syndrome after breast cancer.
    Le Deley MC; Suzan F; Cutuli B; Delaloge S; Shamsaldin A; Linassier C; Clisant S; de Vathaire F; Fenaux P; Hill C
    J Clin Oncol; 2007 Jan; 25(3):292-300. PubMed ID: 17159192
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Acute myeloid leukemia after adjuvant breast cancer therapy in older women: understanding risk.
    Patt DA; Duan Z; Fang S; Hortobagyi GN; Giordano SH
    J Clin Oncol; 2007 Sep; 25(25):3871-6. PubMed ID: 17664457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors before autologous stem-cell transplantation for lymphoma predict for secondary myelodysplasia and acute myelogenous leukemia.
    Kalaycio M; Rybicki L; Pohlman B; Sobecks R; Andresen S; Kuczkowski E; Bolwell B
    J Clin Oncol; 2006 Aug; 24(22):3604-10. PubMed ID: 16877727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy and cardiotoxicity in older breast cancer patients: a population-based study.
    Doyle JJ; Neugut AI; Jacobson JS; Grann VR; Hershman DL
    J Clin Oncol; 2005 Dec; 23(34):8597-605. PubMed ID: 16314622
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of acute myeloid leukemia and myelodysplastic syndrome in trials of adjuvant epirubicin for early breast cancer: correlation with doses of epirubicin and cyclophosphamide.
    Praga C; Bergh J; Bliss J; Bonneterre J; Cesana B; Coombes RC; Fargeot P; Folin A; Fumoleau P; Giuliani R; Kerbrat P; Hery M; Nilsson J; Onida F; Piccart M; Shepherd L; Therasse P; Wils J; Rogers D
    J Clin Oncol; 2005 Jun; 23(18):4179-91. PubMed ID: 15961765
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Warren JL; Brown ML
    J Natl Cancer Inst; 2007 Jul; 99(13):1050; author reply 1051-2. PubMed ID: 17596580
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Clavarezza M; Del Mastro L; Pronzato P; Bruzzi P; Venturini M
    J Natl Cancer Inst; 2007 Jul; 99(13):1050-1; author reply 1051-2. PubMed ID: 17596581
    [No Abstract]   [Full Text] [Related]  

  • 9. Myelodysplastic syndrome and acute myeloid leukemia following adjuvant chemotherapy with and without granulocyte colony-stimulating factors for breast cancer.
    Calip GS; Malmgren JA; Lee WJ; Schwartz SM; Kaplan HG
    Breast Cancer Res Treat; 2015 Nov; 154(1):133-43. PubMed ID: 26450505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
    Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
    Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surgeon characteristics and receipt of adjuvant radiotherapy in women with breast cancer.
    Hershman DL; Buono D; McBride RB; Tsai WY; Joseph KA; Grann VR; Jacobson JS
    J Natl Cancer Inst; 2008 Feb; 100(3):199-206. PubMed ID: 18230795
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk of dementia in older breast cancer survivors: a population-based cohort study of the association with adjuvant chemotherapy.
    Baxter NN; Durham SB; Phillips KA; Habermann EB; Virning BA
    J Am Geriatr Soc; 2009 Mar; 57(3):403-11. PubMed ID: 19278395
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of radiation therapy for older women with early breast cancer.
    Smith BD; Gross CP; Smith GL; Galusha DH; Bekelman JE; Haffty BG
    J Natl Cancer Inst; 2006 May; 98(10):681-90. PubMed ID: 16705122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia.
    Hofmann WK; Heil G; Zander C; Wiebe S; Ottmann OG; Bergmann L; Hoeffken K; Fischer JT; Knuth A; Kolbe K; Schmoll HJ; Langer W; Westerhausen M; Koelbel CB; Hoelzer D; Ganser A
    Ann Hematol; 2004 Aug; 83(8):498-503. PubMed ID: 15156346
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Delay of adjuvant chemotherapy initiation following breast cancer surgery among elderly women.
    Hershman DL; Wang X; McBride R; Jacobson JS; Grann VR; Neugut AI
    Breast Cancer Res Treat; 2006 Oct; 99(3):313-21. PubMed ID: 16583264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Granulocyte colony-stimulating factor: key (f)actor or innocent bystander in the development of secondary myeloid malignancy?
    Touw IP; Bontenbal M
    J Natl Cancer Inst; 2007 Feb; 99(3):183-6. PubMed ID: 17284707
    [No Abstract]   [Full Text] [Related]  

  • 17. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematopoietic growth factors in patients receiving intensive chemotherapy for malignant disorders: studies of granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony stimulating factor (GM-CSF), interleukin-3 (IL-3) and Flt-3 ligand (Flt3L).
    Bruserud O; Foss B; Petersen H
    Eur Cytokine Netw; 2001; 12(2):231-8. PubMed ID: 11399510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease.
    Tebbi CK; London WB; Friedman D; Villaluna D; De Alarcon PA; Constine LS; Mendenhall NP; Sposto R; Chauvenet A; Schwartz CL
    J Clin Oncol; 2007 Feb; 25(5):493-500. PubMed ID: 17290056
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acute myeloid leukemia and myelodysplastic syndrome after doxorubicin-cyclophosphamide adjuvant therapy for operable breast cancer: the National Surgical Adjuvant Breast and Bowel Project Experience.
    Smith RE; Bryant J; DeCillis A; Anderson S;
    J Clin Oncol; 2003 Apr; 21(7):1195-204. PubMed ID: 12663705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 108.